Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

(2020) James Chih-Hsin Yang et al.   Journal of Thoracic Oncology

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

(2019) Alessandro Russo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation

(2019) Ou Yamaguchi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer

(2019) Hisashi Tanaka et al.   MEDICAL ONCOLOGY

Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment

(2019) Tianli Zhang et al.   Translational Lung Cancer Research

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

(2018) D Westover et al.   ANNALS OF ONCOLOGY

Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer

(2018) Victor H.F. Lee   Asia-Pacific Journal of Clinical Oncology

Squamous Cell Carcinoma Transformation from EGFR-mutated Lung Adenocarcinoma: A Case Report and Literature Review

(2018) Hiroki Izumi et al.   Clinical Lung Cancer

A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations

(2018) Hisao Imai et al.   LUNG CANCER

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer

(2017) Emily Castellanos et al.   Journal of Thoracic Oncology

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations

(2017) Kentaro Tanaka et al.   Oncotarget

Effect of dose adjustment on the safety and efficacy of afatinib forEGFRmutation-positive lung adenocarcinoma:post hocanalyses of the randomized LUX-Lung 3 and 6 trials

(2016) J. C.-H. Yang et al.   ANNALS OF ONCOLOGY

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

(2015) James C-H Yang et al.   LANCET ONCOLOGY

Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer

(2009) Kyoichi Kaira et al.   LUNG CANCER